Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quintiles And Eisai Collaborate To Develop Cancer Compounds

This article was originally published in PharmAsia News

Executive Summary

Moving beyond the traditional contract research organization model, Quintiles will collaborate with Eisai to perform 11 proof-of-concept trials on six oncology compounds in a deal announced Oct. 30

You may also be interested in...



Eisai Hits First Milestone In Risk-sharing Alliance With Quintiles

Eisai’s lenvatinib achieved proof of concept for melanoma, and now Eisai steps back into the picture for Phase III.

SFJ Pharma Selling Geographic And Indication Expansion, One Compound At A Time

Pfizer Inc. and Eisai Co.'s downsized R&D budgets seek no-risk solutions with SFJ Pharma.

Takeda Goes Virtual, Splitting Non-oncology Development Between Covance And Quintiles

TOKYO - Takeda Pharmaceuticals has teamed with contract research organizations Covance and Quintiles to move toward a "fully virtual outsourcing model," the company announced Feb. 15

Related Content

UsernamePublicRestriction

Register

SC070375

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel